{
    "symbol": "HSDT",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-15 19:08:03",
    "content": " The second quarter saw the first commercial sales of our Portable Neuromodulation Stimulator or PoNS device which is indicated in the U.S. for short-term treatment of gait deficit due to mild to moderate symptoms of multiple sclerosis, MS and is to be used in conjunction with a supervised therapeutic exercise program. As we disclosed in our second quarter 10-Q, certain performance criteria were achieved for outstanding performance-based stock options in August, resulting in the vesting of performance-based stock options, for which, we will recognize a onetime noncash share-based compensation expense of approximately $1.2 million in this third quarter."
}